Fenebrutinib Found Effective in Suppressing Relapsing Multiple Sclerosis Disease Activity
Results of the FENopta study found that after one year of treatment, 96% of patients experienced no relapses of multiple sclerosis, with an annualized relapse rate of just 0.04.
